Leadership Cardiovascolare e Metabolico
James F. List, M.D., Ph.D., è il responsabile dell’area terapeutica globale Cardiovascolare e Metabolico (CVM) e dirige un team globale che lavora alla creazione di nuove soluzioni per il miglioramento delle cure per il diabete e le patologie cardiovascolari e l’intercettazione della malattia. Jim ha una responsabilità end-to-end relativa a ricerca e sviluppo per il portafoglio CVM di Janssen, tra cui la scoperta di farmaci, lo sviluppo clinico e l’innovazione esterna. Jim è entrato a far parte di Janssen nel 2014.
Prima di unirsi a Janssen, James ha lavorato presso Bristol-Myers Squibb in qualità di vicepresidente, Sviluppo del diabete, rivestendo un ruolo di responsabilità per la joint venture sul diabete con AstraZeneca.
In precedenza, James è stato un membro di facoltà della Harvard Medical School di Boston, Massachusetts (USA) ed è responsabile clinico dell’area Endocrinologia generale e tiroide. Si è laureato alla Stanford University in California (USA), e ha completato la sua specializzazione in medicina e il dottorato di ricerca presso l’Università del Minnesota a Minneapolis, Minnesota (USA). Ha completato la sua formazione medica presso il Brigham and Women’s Hospital, il Boston Children’s Hospital e il Massachusetts General Hospital, a Boston, Massachusetts (USA), oltre ad aver ottenuto la certificazione in medicina interna, pediatria ed endocrinologia.
James F. List, M.D., Ph.D.
Responsabile dell’area terapeutica globale, Cardiovascolare e Metabolico
Calvin Schmidt is Global Commercial Strategy Leader (GCSL) for the Cardiovascular & Metabolism (CVM) therapeutic area and the GCSL for the newly created Johnson & Johnson Innovation World Without Disease Accelerator (WWDA).
CVM is maximizing the value of pipeline and marketed assets and developing innovative solutions for patients, providers and healthcare systems globally by working closely with R&D and BD toward the goal of longer, healthier lives for patients with the world’s most common chronic diseases.
WWDA strengthens Johnson & Johnson’s focus on creating solutions that eliminate disease through early detection, prevention, interception and cure. The WWD Accelerator will identify innovation wherever it originates, internally and externally; leverage relevant capabilities and competencies; build strategic alliances; and seed transformative growth opportunities, by working closely with R&D, BD and Innovation centers across the enterprise.
Prior to this role, he was President of Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, where he led the growth of a business that is making a significant difference for patients suffering from cardiovascular and metabolic diseases. In addition, with extensive international and emerging market experience, Calvin also oversaw the strategic management of Janssen’s portfolio of products in Puerto Rico.
Previously, Calvin was Worldwide Vice President, Human Resources, for the Johnson & Johnson Group of Consumer Companies, a member of the Consumer Group Operating Committee, and a member of the Johnson & Johnson Enterprise Human Resources Executive Committee and served as the first President of Wellness & Prevention, Inc., a Johnson & Johnson company, focused on helping organizations prevent chronic disease and sustain good health for their employees and members.
Other roles at Johnson & Johnson included General Manager, Johnson & Johnson Merck Joint Venture and Global Vice President, Marketing and Sales, for McNeil Nutritionals. Before joining Johnson & Johnson, Calvin was with Mars, Inc. for nearly 15 years, holding domestic and international leadership positions in operations, R&D, product development, marketing and general management.
In September 2017, Calvin was appointed to represent Johnson & Johnson on the Healthcare Leadership Council (HLC), a coalition of top executives from companies representing many sectors in the U.S. health system. In January 2015, he was named to the American Diabetes Association (ADA) Board of Directors, underscoring his dedication to combat the growing epidemic of diabetes; in 2016, he was named Chair of the ADA’s Audit Committee and in 2017 he was also named Chair of the ADA’s CEO search committee.
Calvin holds Master of Business Administration in Marketing and Finance from Capital University in Columbus, Ohio, and a Bachelor of Engineering in Electrical Engineering from Vanderbilt University.